Latest Period
Q2 2026
Security Snapshot
Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) Institutional Ownership
CUSIP: 25056L103
13F Institutional Holders and Ownership History from Q1 2021 to Q2 2026
Institutions Reporting
136
Shares (Excl. Options)
43,301,243
Price
$14.47
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- DSGN on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 43,301,243
- Total 13F value
- $626,399,809
- Portfolio coverage rank
- 0%
- Share change
- +5,358,722
- Value change
- +$94,116,043
- Number of holders
- 136
- Shares outstanding
- 62,778,274
- SEC-reported price per share
- $12.18
- Insider filing price
- $12.18
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DSGN - Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 25056L103.
- 136 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 124 to 136 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $404,113,091 to $626,399,809.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 136 institutions filings for Q2 2026.
Security key
25056L103
Latest holder period
Q2 2026
13F holders
136
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
DSGN full holder history
Design Therapeutics, Inc. SEC filings
Design Therapeutics, Inc. company facts
Design Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 25056L103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
DSGN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| SR One Capital Fund I Aggregator LP | 11% | $62,048,106 | 6,607,892 | Simeon George | 09 Mar 2026 | |||
| Sirenia Capital Management LP | 9.5% | $93,275,959 | 5,963,936 | Sirenia Capital Management LP | 30 Jun 2026 | |||
| Light Irrevocable Trust #1 dated April 22, 2019 | 6.9% | $16,257,665 | 3,834,355 | Light Irrevocable Trust #1 dated April 22, 2019 | 31 Dec 2024 | |||
| Star Irrevocable Trust #1 dated April 22, 2019 | 6.9% | $16,257,665 | 3,834,355 | Star Irrevocable Trust #1 dated April 22, 2019 | 31 Dec 2024 | |||
| Logos Global Management LP | 4.4% | -22% | $16,322,350 | -$4,802,600 | 2,515,000 | -23% | Arsani William | 14 Nov 2025 |
| Point72 Asset Management, L.P. | 3.8% | -26% | $37,011,325 | -$13,001,704 | 2,366,453 | -26% | Point72 Asset Management, L.P. | 30 Jun 2026 |
As of 30 Jun 2026, 136 institutional investors reported holding 43,301,243 shares of Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN). This represents 69% of the company’s total 62,778,274 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
60%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SR One Capital Management, LP | 10% | 6,526,476 | 0% | 9.1% | $94,438,108 |
| Logos Global Management LP | 4.8% | 3,000,000 | +54% | 1.9% | $43,410,000 |
| BAKER BROS. ADVISORS LP | 4.3% | 2,678,430 | +3.6% | 0.19% | $38,756,882 |
| Driehaus Capital Management LLC | 4.2% | 2,661,115 | +53% | 0.22% | $38,506,334 |
| BlackRock, Inc. | 4.2% | 2,660,024 | +25% | 0% | $38,490,551 |
| Point72 Asset Management, L.P. | 3.8% | 2,366,453 | -13% | 0.05% | $34,242,575 |
| Trails Edge Capital Partners, LP | 3.2% | 2,001,282 | +135% | 4.6% | $28,958,550 |
| Frazier Life Sciences Management, L.P. | 2.9% | 1,809,854 | 0.57% | $26,188,587 | |
| Vivo Capital, LLC | 2.6% | 1,612,903 | 0% | 2.1% | $23,338,706 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 1,571,022 | +16% | 0% | $22,732,688 |
| Caption Management, LLC | 1.8% | 1,118,098 | +1189% | 0.57% | $16,178,878 |
| Almitas Capital LLC | 1.6% | 1,026,893 | -33% | 3.6% | $14,859,142 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 958,417 | +38% | 0% | $13,871,597 |
| Sofinnova Investments, Inc. | 1.4% | 865,135 | 0.67% | $12,518,503 | |
| FMR LLC | 1.2% | 776,462 | -2.7% | 0% | $11,235,405 |
| MORGAN STANLEY | 1.2% | 765,425 | +17% | 0% | $11,075,699 |
| STATE STREET CORP | 1.2% | 736,221 | +12% | 0% | $10,653,118 |
| Woodline Partners LP | 1.1% | 700,354 | -27% | 0.03% | $10,134,122 |
| DIMENSIONAL FUND ADVISORS LP | 1.1% | 694,743 | +61% | 0% | $10,051,800 |
| GOLDMAN SACHS GROUP INC | 1% | 656,584 | +30% | 0% | $9,500,771 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.9% | 565,597 | +95% | 0.03% | $8,184,189 |
| ACADIAN ASSET MANAGEMENT LLC | 0.86% | 537,479 | -13% | 0.01% | $7,774,000 |
| Siren, L.L.C. | 0.83% | 523,212 | 0.15% | $7,570,878 | |
| Qube Research & Technologies Ltd | 0.7% | 437,079 | +1179% | 0.01% | $6,324,533 |
| RENAISSANCE TECHNOLOGIES LLC | 0.62% | 387,913 | -5% | 0.01% | $5,613,101 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
22
Latest
Q2 2026
Rows shown
1-22 of 22
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 43,301,243 | $626,399,809 | +$94,116,043 | $14.47 | 136 |
| 2026 Q1 | 37,986,585 | $404,113,091 | -$602,819 | $10.64 | 124 |
| 2025 Q4 | 38,119,020 | $357,552,417 | +$35,421,791 | $9.38 | 116 |
| 2025 Q3 | 34,492,564 | $259,728,206 | +$644,093 | $7.53 | 94 |
| 2025 Q2 | 34,530,294 | $116,365,282 | +$265,374 | $3.37 | 91 |
| 2025 Q1 | 34,459,430 | $133,014,167 | +$2,133,109 | $3.86 | 95 |
| 2024 Q4 | 33,460,789 | $206,451,772 | +$9,368,489 | $6.17 | 94 |
| 2024 Q3 | 32,032,058 | $172,330,017 | +$1,330,349 | $5.38 | 98 |
| 2024 Q2 | 32,097,220 | $107,523,187 | +$4,413,890 | $3.35 | 92 |
| 2024 Q1 | 30,700,544 | $123,722,605 | -$3,107,582 | $4.03 | 88 |
| 2023 Q4 | 31,717,256 | $84,046,693 | -$1,847,569 | $2.65 | 87 |
| 2023 Q3 | 32,867,255 | $77,567,491 | -$67,849,061 | $2.36 | 84 |
| 2023 Q2 | 38,786,588 | $244,358,163 | +$738,881 | $6.30 | 96 |
| 2023 Q1 | 38,691,853 | $223,252,292 | -$16,074,747 | $5.77 | 94 |
| 2022 Q4 | 40,381,322 | $414,296,202 | -$600,847 | $10.26 | 81 |
| 2022 Q3 | 39,933,593 | $667,698,632 | +$24,544,231 | $16.72 | 76 |
| 2022 Q2 | 38,690,076 | $541,665,132 | +$9,157,438 | $14.00 | 70 |
| 2022 Q1 | 37,990,461 | $613,724,140 | +$27,782,038 | $16.15 | 62 |
| 2021 Q4 | 36,170,094 | $773,127,906 | +$50,180,616 | $21.41 | 58 |
| 2021 Q3 | 28,281,317 | $414,830,000 | +$5,824,856 | $14.69 | 52 |
| 2021 Q2 | 27,817,792 | $545,865,000 | +$37,059,194 | $19.89 | 49 |
| 2021 Q1 | 25,762,953 | $755,185,000 | +$755,158,004 | $29.90 | 43 |